Morgan Stanley raised the firm’s price target on Sarepta to $200 from $165 and keeps an Overweight rating on the shares. The firm views Elevidys label expansion, including accelerated approval in non-ambulatory patients, as better than expected, setting the stage for rapid acceleration in sale growth later this year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta (NASDAQ:SRPT) Soars on Accelerated FDA Approval for Elevidys
- Biotech Alert: Searches spiking for these stocks today
- FDA’s Sarepta decision ‘positive’ for gene therapy, STATNews reports
- Sarepta price target raised to $235 from $166 at Needham
- Sarepta price target raised to $223 from $215 at Goldman Sachs